Goodwin Procter LLP advised Enterprise Therapeutics Ltd on the deal.
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, announced its novel TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group. The portfolio includes ETD002 which recently entered Phase 1 trials.
Enterprise’s shareholders received an upfront payment of £75 million and are eligible to receive additional contingent payments, to be made based on the achievement of certain predetermined milestones.The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion. Enterprise is backed by leading life science investors Epidarex Capital, Forbion, IP Group, Novartis Venture Fund and Versant Ventures.
The Goodwin team on the Enterprise matter was led by Graham Defries (Picture) and Andrew Harrow and included Malcolm Bates, Gretchen Scott, Michael Grainger, Kenny Walker-Durrant, Talitha Shkopiak, Matthew Shelley, Josh Skyring, Samantha Deacon, Zena Hadjiargyrou, Leah Black, Rob Young, Amy Francis, Daniel Karelitz, Nicole Spiteri, Grace Wirth and James Devendorf.
Involved fees earner: Talitha Shkopiak – Goodwin Knight Law LLP; Malcolm Bates – Goodwin Procter; Samantha Deacon – Goodwin Procter; Graham Defries – Goodwin Procter; James Devendorf – Goodwin Procter; Amy Francis – Goodwin Procter; Michael Grainger – Goodwin Procter; Andrew Harrow – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Gretchen Scott – Goodwin Procter; Matthew Shelley – Goodwin Procter; Joshua Skyring – Goodwin Procter; Nicole Spiteri – Goodwin Procter; Kenny Walker-Durrant – Goodwin Procter; Grace Wirth – Goodwin Procter; Robert Young – Goodwin Procter;
Clients: Enterprise Therapeutics Ltd;